Teva Struggles To Sell 2014 Guidance, Blue-Sky Estimates For NTE Program
Executive Summary
The Israeli generics giant unveiled two sets of 2014 guidance, allowing for different levels of competition for Copaxone. But Wall Street sees the company slowing the pace of cost-cutting and providing overly optimistic revenue estimates for new therapeutic entities.
You may also be interested in...
A More Disciplined Teva Gets Lukewarm Reception From Street
More organizational and strategic discipline, far greater selectivity in R&D and business development, and emphasis on profitable, not top-line, growth are at the core of the strategy put forth by Teva’s new management on Dec. 11. The reboot makes sense, given the company’s relentless focus on M&A over the past decade and its maturing generics businesses, so why are investors balking?
New Data Position Lazertinib As Strong Contender In 1L NSCLC
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.
Supreme Court Seems To Support Government’s Later Dismissal Of False Claims Act Case
Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.